Skip to main content
Figure 4 | BMC Genetics

Figure 4

From: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients

Figure 4

Re-expression of PTPRO following treatment with 5-AzaC. (a) Breast cancer cell lines MCF-7 and MDA-MB-231 were treated with 1 μM 5-AzaC for 72 h and 2.5 μM 5-AzaC for 96 h, respectively. Total RNA from cells was subjected to RT-PCR to amplify PTPRO mRNA. 18S rRNA was used for normalization; (b) MSP analysis of PTPRO methylation status in breast cancer cell lines with or without 5-AzaC treatment. M, methylated; U, unmethylated.

Back to article page

BMC Genomic Data

ISSN: 2730-6844

Contact us